GT Biopharma is trading 7.1% up at $0.30 after rebounding from its August 17, 2026 close of $0.28.
- No fresh company-specific announcement was identified on August 18, 2026.
- The August 14 quarterly report cited approximately $5.1 million in cash and operational runway through the fourth quarter of 2026.
- With the broader market weaker, the move appears to be a limited rebound rather than a confirmed catalyst.